科研之友
微信
新浪微博
Facebook
分享链接
摘要
Over the course of the last three decades our approach to the management of dyslipidemia has intensified on the basis of randomized controlled trials demonstrating reduction in cardiovascular events. However, the presence of a substantial residual risk and complex dyslipidemic states presents an ongoing challenge in clinical practice. The current controversies and opportunities in the management of both atherogenic and protective lipid factors will be reviewed.
- 出版日期2014
